{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:25:35Z","timestamp":1792481135612,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,12]]},"abstract":"<jats:p>Ozanimod was approved in the United States in March 2020 for the treatment of relapsing multiple sclerosis and subsequently in 2021 for moderately to severely active ulcerative colitis. However, there is limited information available on the adverse drug events associated with its use. The main objective of this study was to explore the safety of Ozanimod after its market launch. Data was gathered from the United States Food and Drug Administration Adverse Event Reporting System database. To detect safety signals associated with Ozanimod adverse events, disproportionality analyses were performed using the reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker algorithms. We extracted 7,118,789 reports from the FDA Adverse Event Reporting System database, of which 5429 reports identified Ozanimod as the primary suspect drug. Adverse reactions attributed to Ozanimod manifested across 26 organ systems, encompassing a total of 90 preferred terms meeting the criteria of all 4 algorithms simultaneously. In our study, back pain, hypertension, increased blood pressure, elevated hepatic enzymes, abnormal hepatic enzymes, pollakiuria, micturition urgency, and herpes zoster were consistent with the results of clinical trials. Notably, we observed some common adverse drug reaction signals, such as hypesthesia, muscle spasms, balance disorder, and gait disturbance, which were not documented in the official drug label. The majority of adverse events occurred within the initial 30 days following the initiation of Ozanimod treatment. Ozanimod presents the potential for diverse adverse reactions alongside its therapeutic benefits. Hence, in clinical practice, prompt detection of adverse drug reactions and the implementation of timely and effective preventive measures are essential.<\/jats:p>","DOI":"10.1097\/md.0000000000044535","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T21:00:18Z","timestamp":1757970018000},"page":"e44535","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A real-world data analysis of Ozanimod in the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1097","volume":"104","author":[{"given":"Qinhui","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmeng","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-2491","authenticated-orcid":false,"given":"Xiaolin","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260923","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","article-title":"Ozanimod: first approval.","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"R2-20260923","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity.","volume":"173","author":"Scott","year":"2016","journal-title":"Br J Pharmacol"},{"key":"R3-20260923","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of Ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"R4-20260923","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.3390\/jcm12155014","article-title":"Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis.","volume":"12","author":"Bencardino","year":"2023","journal-title":"J Clin Med"},{"key":"R5-20260923","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/cer-2019-0169","article-title":"Comparative safety and efficacy of Ozanimod versus fingolimod for relapsing multiple sclerosis.","volume":"9","author":"Swallow","year":"2020","journal-title":"J Comp Eff Res"},{"key":"R6-20260923","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","article-title":"Efficacy and safety of approximately 3 years of continuous Ozanimod in moderately to severely active ulcerative colitis: interim analysis of the true north open-label extension.","volume":"18","author":"Danese","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R7-20260923","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/14740338.2023.2251390","article-title":"Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system.","volume":"23","author":"Cao","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"R8-20260923","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11096-022-01397-5","article-title":"A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data.","volume":"44","author":"Wei","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"R9-20260923","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/14740338.2023.2251881","article-title":"A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data.","volume":"23","author":"Yan","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"R10-20260923","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system.","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"},{"key":"R11-20260923","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R12-20260923","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R13-20260923","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-20260923","first-page":"201","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system.","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am Stat"},{"key":"R15-20260923","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database.","volume":"19","author":"Zhao","year":"2023","journal-title":"Exp Opin Drug Metab Toxicol"},{"key":"R16-20260923","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of Ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"R17-20260923","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/1352458518789884","article-title":"Efficacy and safety of Ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study.","volume":"25","author":"Cohen","year":"2019","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"R18-20260923","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis.","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"R19-20260923","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition.","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"key":"R20-20260923","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"R21-20260923","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review.","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"R22-20260923","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40263-024-01116-w","article-title":"Ozanimod: a review in relapsing forms of multiple sclerosis.","volume":"38","author":"Nie","year":"2024","journal-title":"Cns Drugs"},{"key":"R23-20260923","first-page":"2170","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (vol 391, pg 1263, 2018).","volume":"392","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"R24-20260923","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"R25-20260923","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ana.21227","article-title":"FTY720 modulates human oligodendrocyte progenitor process extension and survival.","volume":"63","author":"Miron","year":"2007","journal-title":"Ann Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:00:33Z","timestamp":1790186433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":25,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044535","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}